1026149-54-1

Basic information

• Product Name: 5-[1-{4-[2-(Benzooxazol-2-yl-methyl-amino)-1-phenyl-ethoxy]-phenyl}-meth-(Z)-ylidene]-thiazolidine-2,4-dione
• CAS NO: 1026149-54-1
• Molecular Weight: 471.536
• Mol File: 1026149-54-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5-[1-{4-[2-(Benzooxazol-2-yl-methyl-amino)-1-phenyl-ethoxy]-phenyl}-meth-(Z)-ylidene]-thiazolidine-2,4-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 5-[1-{4-[2-(Benzooxazol-2-yl-methyl-amino)-1-phenyl-ethoxy]-phenyl}-meth-(Z)-ylidene]-thiazolidine-2,4-dione(1026149-54-1)
• EPA Substance Registry System: 5-[1-{4-[2-(Benzooxazol-2-yl-methyl-amino)-1-phenyl-ethoxy]-phenyl}-meth-(Z)-ylidene]-thiazolidine-2,4-dione(1026149-54-1)

Safety Data

• Hazardous Substances Data: 1026149-54-1(Hazardous Substances Data)

Upstream product

• 1026429-07-1 2-(Benzooxazol-2-yl-methyl-amino)-1-phenyl-ethanol 
• 615-18-9 2-chloro-1,3-benzoxazole 
• 68579-60-2 2-(methylamino)-1-phenylethanol 
• 2295-31-0 thiazoline-2,4-dione 
• 1027189-53-2 4-[2-(Benzooxazol-2-yl-methyl-amino)-1-phenyl-ethoxy]-benzaldehyde 

Relevant articles and documents

benzyl>-2,4-thiazolidinediones as Potent Antihyperglycemic Agents

A series of -2,4-thiazolidinediones and benzyl>-2,4-thiazolidinediones was synthesized from the corresponding aldehydes.Compounds from the urea series, exemplified by 16, showed antihyperglycemic potency comparable with known agents of the type such as pioglitazone and troglitazone (CS-045).The benzoxazole 49, a cyclic analogue of 16, was a very potent enhancer of insulin sensitivity, and by modification of the aromatic heterocycle, an aminopyridine, 37, was identified as a lead compound from SAR studies.Evaluation of antihyperglycemic activity together with effects on blood hemoglobin content, to determine the therapeutic index, was performed in 8-day repeat administration studies in genetically obese C57 BI/6 ob/ob mice.From these studies, BRL 49653 (37) has been selected, on the basis of antihyperglycemic potency combined with enhanced selectivity against reductions in blood hemoglobin content, for further evaluation.